New gene therapy strategies for cancer treatment: A review of recent patents

Recent Patents on Anti-Cancer Drug Discovery

Volumn 7, Issue 3, 2012, Pages 297-312

  Ortiz, Raúl ^a   Melguizo, Consolación ^b   Prados, José ^b   Álvarez, Pablo J ^b   Caba, Octavio ^a   Rodríguez Serrano, Fernando ^b   Hita, Fidel ^a   Aránega, Antonia ^b  

^a UNIVERSITY OF JAÉN   (Spain)

^b Institute of Biopathology and Regenerative Medicine IBIMER   (Spain)

Author keywords

Cancer therapy; Combined therapy; Drug resistance; Gene therapy; Patent; Vectors

Indexed keywords

ADENOVIRUS VECTOR; ANGIOSTATIN; BACTERIAL VECTOR; BETA INTERFERON; GANCICLOVIR; GENDICINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HERPESVIRUS VECTOR; INTERFERON; INTERLEUKIN 2; IPILIMUMAB; LENTIVIRUS VECTOR; LONTUCIREV; MELANOMA VACCINE; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; ONCOLYTIC ADENOVIRUS; ONCOLYTIC HERPES VIRUS; ONCOLYTIC RESPIRATORY SYNCYTIAL VIRUS; ONCOLYTIC VIRUS; ONCORINE; PARVOVIRUS VECTOR; PEXASTIMOGENE DEVACIREPVEC; PLACEBO; PROTEIN BCL 2; RETINOBLASTOMA PROTEIN; RETROVIRUS VECTOR; ROMIDEPSIN; SHORT HAIRPIN RNA; THYMIDINE KINASE; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIANGIOGENIC ACTIVITY; BLADDER CARCINOMA; BREAST CANCER; CANCER GENE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CAUSE OF DEATH; CELL ACTIVATION; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; CYTOKINE PRODUCTION; CYTOLOGY; DIGESTIVE SYSTEM CANCER; DRUG POTENTIATION; DRUG TARGETING; ENZYME INHIBITION; ENZYME PRODRUG THERAPY; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GENE FUNCTION; GENE TRANSFER; GENE VECTOR; GLIOBLASTOMA; HEAD AND NECK CANCER; HERPES SIMPLEX VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; KIDNEY CANCER; KIDNEY CARCINOMA; LISTERIA; LIVER CANCER; LIVER METASTASIS; LUNG CANCER; LUNG METASTASIS; LYMPH NODE METASTASIS; M PHASE CELL CYCLE CHECKPOINT; MALIGNANT NEOPLASTIC DISEASE; MEDICAL DECISION MAKING; MELANOMA; MOLECULAR BIOLOGY; MOUTH CANCER; MULTIPLE MYELOMA; OVARY CANCER; PANCREAS CANCER; PATENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RNA INTERFERENCE; SALMONELLA; SHIGELLA; SUICIDE GENE THERAPY; TREATMENT FAILURE; TREATMENT OUTCOME; VIRAL GENE DELIVERY SYSTEM; YERSINIA;

ANIMALS; GENE SILENCING; GENES, TRANSGENIC, SUICIDE; GENETIC THERAPY; GENETIC VECTORS; HUMANS; IMMUNOMODULATION; MODELS, BIOLOGICAL; NEOPLASMS; PATENTS AS TOPIC; THERAPIES, INVESTIGATIONAL;

EID: 84867495468     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489212801820093     Document Type: Review

References (165)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127(12): 2893-917.
2. Bonini C, Gansbacher B. Cancer gene therapy: Present and future. Hum Gene Ther 2009; 20(10): 1100.
3. Cao S, Cripps A, Wei MQ. New strategies for cancer gene therapy: Progress and opportunities. Clin Exp Pharmacol Physiol 2010; 37(1): 108-14.
4. Alexandrova R. Experimental strategies in gene therapy of cancer. J BUON 2009; 14 (Suppl 1): S23-32.
5. Hamada N, Matsumoto H, Hara T, Kobayashi Y. Intercellular and intracellular signaling pathways mediating ionizing radiationinduced bystander effects. J Radiat Res (Tokyo) 2007; 48(2): 87-95.
6. Durai R, Yang SY, Seifalian AM, Winslet MC. Principles and applications of gene therapy in colon cancer. J Gastrointestin Liver Dis 2008; 17(1): 59-67.
7. Walther W, Stein U. Viral vectors for gene transfer: A review of their use in the treatment of human diseases. Drugs 2000; 60(2): 249-71.
8. Sheridan C. Gene therapy finds its niche. Nat Biotechnol 2011; 29(2): 121-8.
9. Wu TL, Ertl HC. Immune barriers to successful gene therapy. Trends Mol Med 2009; 15(1): 32-9.
10. Heldwein EE, Krummenacher C. Entry of herpes viruses into mammalian cells. Cell Mol Life Sci 2008; 65(11): 1653-68.
11. Jones C. Herpes simplex virus type 1 and bovine herpes virus 1 latency. Clin Microbiol Rev 2003; 16(1): 79-95.
12. Halford WP, Kemp CD, Isler JA, Davido DJ, Schaffer PA. ICP0, ICP4, or VP16 expressed from adenovirus vectors induces reactivation of latent herpes simplex virus type 1 in primary cultures of latently infected trigeminal ganglion cells. J Virol 2001; 75(13): 6143-53.
13. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995; 1(9): 938-43.
14. Nakano K, Todo T, Chijiiwa K, Tanaka M. Therapeutic efficacy of G207, a conditionally replicating herpes simplex virus type 1 mutant, for gallbladder carcinoma in immunocompetent hamsters. Mol Ther 2001; 3(4): 431-7.
15. Geevarghese SK, Geller DA, de Haan HA, Horer M, Knoll AE, Mescheder A, et al. Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver. Hum Gene Ther 2010; 21(9): 1119-28.
16. Fong Y, Kim T, Bhargava A, Schwartz L, Brown K, Brody L, et al. A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer. Mol Ther 2009; 17(2): 389-94.
17. Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009; 27(34): 5763-71.
18. Brown, S.M., Conner, J. Herpes simplex virus complex. WO03068809 (2003).
19. Weidong, Z., Lixian, J., Calvin, C. Breast cancer therapy using an engineered respiratory syncytial virus. WO2011146100 (2011).
20. Grandpre LE, Duke-Cohan JS, Ewald BA, Devoy C, Barouch DH, Letvin NL, et al. Immunogenicity of recombinant modified vaccinia ankara following a single or multi-dose vaccine regimen in rhesus monkeys. Vaccine 2009; 27(10): 1549-56.
21. McFadden G. Poxvirus tropism. Nat Rev Microbiol 2005; 3(3): 201-13.
22. Buller RM, Chakrabarti S, Cooper JA, Twardzik DR, Moss B. Deletion of the vaccinia virus growth factor gene reduces virus virulence. J Virol 1988; 62(3): 866-74.
23. Kirn DH, Thorne SH. Targeted and armed oncolytic poxviruses: A novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer 2009; 9(1): 64-71.
24. Thorne SH, Hwang TH, O'Gorman WE, Bartlett DL, Sei S, Kanji F, et al. Rational strain selection and engineering creates a broadspectrum, systemically effective oncolytic poxvirus, JX-963. J Clin Invest 2007; 117(11): 3350-8.
25. Meyer H, Sutter G, Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol 1991; 72 (Pt 5): 1031-8.
26. Amato RJ, Shingler W, Goonewardena M, de Belin J, Naylor S, Jac J, et al. Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFN-alpha): A phase 2 trial. J Immunother 2009; 32(7): 765-72.
27. Park BH, Hwang T, Liu TC, Sze DY, Kim JS, Kwon HC, et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: A phase I trial. Lancet Oncol 2008; 9(6): 533-42.
28. Chaplin, P., Howley, P., Meisinger-Henschel, C. Modified vaccinia ankara virus variant. US7459270 (2011).
29. Lasaro MO, Ertl HC. New insights on adenovirus as vaccine vectors. Mol Ther 2009; 17(8): 1333-9.
30. Biederer C, Ries S, Brandts CH, McCormick F. Replicationselective viruses for cancer therapy. J Mol Med (Berl) 2002; 80(3): 163-75.
31. Tatsis N, Blejer A, Lasaro MO, Hensley SE, Cun A, Tesema L, et al. A CD46-binding chimpanzee adenovirus vector as a vaccine carrier. Mol Ther 2007; 15(3): 608-17.
32. Zhou D, Zhou X, Bian A, Li H, Chen H, Small JC, et al. An efficient method of directly cloning chimpanzee adenovirus as a vaccine vector. Nat Protoc 2010; 5(11): 1775-85.
33. Kamizono J, Nagano S, Murofushi Y, Komiya S, Fujiwara H, Matsuishi T, et al. Survivin-responsive conditionally replicating adenovirus exhibits cancer-specific and efficient viral replication. Cancer Res 2005; 65(12): 5284-91.
34. Wirth T, Zender L, Schulte B, Mundt B, Plentz R, Rudolph KL, et al. A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer. Cancer Res 2003; 63(12): 3181-8.
35. Pfitzenmaier J, Ellis WJ, Arfman EW, Hawley S, McLaughlin PO, Lange PH, et al. Telomerase activity in disseminated prostate cancer cells. BJU Int 2006; 97(6): 1309-13.
36. Lanson NA, Jr., Friedlander PL, Schwarzenberger P, Kolls JK, Wang G. Replication of an adenoviral vector controlled by the human telomerase reverse transcriptase promoter causes tumorselective tumor lysis. Cancer Res 2003; 63(22): 7936-41.
37. Zheng FQ, Xu Y, Yang RJ, Wu B, Tan XH, Qin YD, et al. Combination effect of oncolytic adenovirus therapy and herpes simplex virus thymidine kinase/ganciclovir in hepatic carcinoma animal models. Acta Pharmacol Sin 2009; 30(5): 617-27.
38. Hemminki, A., Kanerva, A., Cerullo, V., Pesonen, S. Adenoviral vectors and methods and uses related thereof. WO2010072900 (2010).
39. Budillon A, Di Gennaro E, Bruzzese F, Rocco M, Manzo G, Caraglia M. Histone deacetylase inhibitors: A new wave of molecular targeted anticancer agents. Recent Pat Anticancer Drug Discov 2007; 2(2): 119-34.
40. Danielsson A, Dzojic H, Rashkova V, Cheng WS, Essand M. The HDAC inhibitor FK228 enhances adenoviral transgene expression by a transduction-independent mechanism but does not increase adenovirus replication. PLoS One 2011; 6(2): e14700.
41. Fujiwara, T., Tanaka, N., Kyo, S. Anticancer agent to be combined with Telomelysin. US20100150884 (2010).
42. Fujiwara T, Urata Y, Tanaka N. Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter. Curr Cancer Drug Targets 2007; 7(2): 191-201.
43. Fujiwara, T., Tanaka, N., Satoru, K., Mizuguchi, H., Hayakawa, T. Telomelysin-GFP gene-containing recombinant virus. EP1795604 (2011).
44. Tanaka T, Huang J, Hirai S, Kuroki M, Watanabe N, Tomihara K, et al. Carcinoembryonic antigen-targeted selective gene therapy for gastric cancer through FZ33 fiber-modified adenovirus vectors. Clin Cancer Res 2006; 12(12): 3803-13.
45. Parrott MB, Adams KE, Mercier GT, Mok H, Campos SK, Barry MA. Metabolically biotinylated adenovirus for cell targeting, ligand screening, and vector purification. Mol Ther 2003; 8(4): 688-700.
46. Korokhov, N., Boureddini, S.C. Targeted adenoviral vector displaying immunoglobulin-binding domain and uses thereof. WO2006085913 (2006).
47. Meruelo, D., Ohno, K. Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A. WO98044132 (1998).
48. Kollipara, K.R. Adeno-associated virus Ezh2 shRNA (AAV 2-EzH2 shRNA) therapy for breast cancer. WO2011111072 (2011).
49. Chang CJ, Yang JY, Xia W, Chen CT, Xie X, Chao CH, et al. EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-{replacement character}{replacement character}-catenin signaling. Cancer Cell 2011; 19(1): 86-100.
50. Vassaux G, Nitcheu J, Jezzard S, Lemoine NR. Bacterial gene therapy strategies. J Pathol 2006; 208(2): 290-8.
51. Wells JM, Mercenier A. Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nat Rev Microbiol 2008; 6(5): 349-62.
52. Tao, L. Novel systems, vectors, and methods for delivery of biomolecules to eukaryotic cells. WO2011150127 (2011).
53. Kim SH, Dass CR. p53-targeted cancer pharmacotherapy: Move towards small molecule compounds. J Pharm Pharmacol 2011; 63(5): 603-10.
54. Di Cintio A, Di Gennaro E, Budillon A. Restoring p53 function in cancer: Novel therapeutic approaches for applying the brakes to tumorigenesis. Recent Pat Anticancer Drug Discov 2010; 5(1): 1-13.
55. Ma G, Shimada H, Hiroshima K, Tada Y, Suzuki N, Tagawa M. Gene medicine for cancer treatment: Commercially available medi cine and accumulated clinical data in China. Drug Des Devel Ther 2009; 2: 115-22.
56. Yang ZX, Wang D, Wang G, Zhang QH, Liu JM, Peng P, et al. Clinical study of recombinant adenovirus-p53 combined with fractionated stereotactic radiotherapy for hepatocellular carcinoma. J Cancer Res Clin Oncol 2010; 136(4): 625-30.
57. Lu W, Zheng S, Li XF, Huang JJ, Zheng X, Li Z. Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: A pilot phase II clinical trial. World J Gastroenterol 2004; 10(24): 3634-8
58. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201. Drugs R D 2007; 8(3): 176-87.
59. Perricaudet, M., Haddada, H., May, E. Defective recombinant adenoviruses for gene therapy of tumors. WO94024297 (1994).
60. Roth, J.A., Mukhopadhyay, T., Tainsky, M.A. Cancer treatment with retroviral vectors comprising wild-type p53. US6998117 (2006).
61. Roth, J.A., Fujiwara, T., Grimm, E.A., Mukhopadhyay, T., Zhang, W., Owen-Schaub, L.B. Methods and compositions comprising DNA damaging agents and p53. US5747469 (1998).
62. Nielsen, L., Horowitz, J.A., Maneval, D.C., Demers, G.W. Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms. EP0969720 (2007).
63. Peng, Z., Zhang, X. Method of reducing side effects of cancer therapy using p53 recombinant adenovirus. US20050281785 (2005).
64. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2002; 2(2): 103-12.
65. Lee, W., Shepard, M.H., Gregory, R., Wills, K., Maneval, D., Lee, E., Goodrich, D., Wang, N. Method of using an adenoviral vector encoding a retinoblastoma protein to treat hyperproliferating cells. US7105156 (2006).
66. Antelman, D., Gregory, R., Wills, K. Methods of treating hyperproliferative disorders using retinoblastoma fusion proteins. US7105156 (2005).
67. Lin J, Page C, Jin X, Sethi AO, Patel R, Nunez G. Suppression activity of pro-apoptotic gene products in cancer cells, a potential application for cancer gene therapy. Anticancer Res 2001; 21(2A): 831-9.
68. Reed, J.C. Methods of using BCL-2 for the therapeutic treatment and prevention of diseases. US7427495 (2008).
69. McDonnell, T., Swisher, S., Fang, B., Bruckheimer, E.M., Sarkiss, M., Ji L., Roth, J. Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codelivery. US20060002895 (2006).
70. Kazhdan, I. Methods and compositions for combinatorial approaches to cancer gene therapy. WO2005049793 (2005).
71. Ohta, S., Asoh, S. Cell death-inducing fused gene acting specifically on cancer and gene product thereof. US7507805 (2009).
72. Nicolini A, Carpi A, Rossi G. Cytokines in breast cancer. Cytokine Growth Factor Rev 2006; 17(5): 325-37.
73. Coveney E, Clary B, Iacobucci M, Philip R, Lyerly K. Active immunotherapy with transiently transfected cytokine-secreting tumor cells inhibits breast cancer metastases in tumor-bearing animals. Surgery 1996; 120(2): 265-72; discussion 72-3.
74. Qin XQ, Tao N, Dergay A, Moy P, Fawell S, Davis A, et al. Interferon-beta gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice. Proc Natl Acad Sci USA 1998; 95(24): 14411-6.
75. Izawa JI, Sweeney P, Perrotte P, Kedar D, Dong Z, Slaton JW, et al. Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis. Clin Cancer Res 2002; 8(4): 1258-70.
76. Quinlin IS, Burnside JS, Dombrowski KE, Phillips CA, Dolby N, Wright SE. Context of MUC1 epitope: Immunogenicity. Oncol Rep 2007; 17(2): 453-6.
77. Liu M, Acres B, Balloul JM, Bizouarne N, Paul S, Slos P, et al. Gene-based vaccines and immunotherapeutics. Proc Natl Acad Sci USA 2004; 101 (Suppl 2): 14567-71.
78. Scholl S, Squiban P, Bizouarne N, Baudin M, Acres B, Von Mensdorff-Pouilly S, et al. Metastatic breast tumor regression following treatment by a gene-modified vaccinia virus expressing MUC1 and IL-2. J Biomed Biotechnol 2003; 2003(3): 194-201.
79. Gansbacher, B. Allogeneic vaccine and methods to synthesize same. US20110257367 (2011).
80. Mansoor W, Gilham DE, Thistlethwaite FC, Hawkins RE. Engineering T cells for cancer therapy. Br J Cancer 2005; 93(10): 1085-91.
81. Schlom, J., Tsang, H., Sam Zaremba, S. Methods of stimulating an immune response against prostate specific antigen. US20110091498 (2011).
82. Simmons, A., Jooss, K., Allison, J. Cancer immunotherapy compositions and methods of use. US7919079 (2011) & WO2007126805 (2007).
83. Sanderson K, Scotland R, Lee P, Liu D, Groshen S, Snively J, et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic Tlymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 2005; 23(4): 741-50.
84. Warren TL, Weiner GJ. Uses of granulocyte-macrophage colonystimulating factor in vaccine development. Curr Opin Hematol 2000; 7(3): 168-73.
85. Kim JJ, Yang JS, Lee DJ, Wilson DM, Nottingham LK, Morrison L, et al. Macrophage colony-stimulating factor can modulate immune responses and attract dendritic cells in vivo. Hum Gene Ther 2000; 11(2): 305-21.
86. Gordon, E.M., Hall, F.L. Targeted vectors for cancer immunotherapy. WO02044394 (2002) & US7708986 (2010).
87. Kirn, D. Oncolytic vaccinia virus cancer therapy. WO2008113078 (2008) & US20100303714 (2010).
88. Breitbach CJ, Burke J, Jonker D, Stephenson J, Haas AR, Chow LQ, et al. Intravenous delivery of a multi-mechanistic cancertargeted oncolytic poxvirus in humans. Nature 2011; 477(7362): 99-102.
89. Callaghan R, Ford RC, Kerr ID. The translocation mechanism of Pglycoprotein. FEBS Lett 2006; 580(4): 1056-63.
90. Prados J, Melguizo C, Carrillo E, Boulaiz H, Marchal JA, Vélez C, et al. Cancer mechanism of multidrug resistance mediated by Pglycoprotein. In: Marchal JA, Gaforio JA, Aránega A, Eds. Trends in basic and applied oncology. Granada: Editorial Universidad de Granada; 2006, pp. 266-83.
91. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. Pglycoprotein: From genomics to mechanism. Oncogene 2003; 22(47): 7468-85.
92. Sorrentino BP, Brandt SJ, Bodine D, Gottesman M, Pastan I, Cline A, et al. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science 1992; 257(5066): 99-103.
93. Cowan KH, Moscow JA, Huang H, Zujewski JA, O'Shaughnessy J, Sorrentino B, et al. Paclitaxel chemotherapy after autologous stemcell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients. Clin Cancer Res 1999; 5(7): 1619-28.
94. Moscow JA, Huang H, Carter C, Hines K, Zujewski J, Cusack G, et al. Engraftment of MDR1 and NeoR gene-transduced hematopoietic cells after breast cancer chemotherapy. Blood 1999; 94(1): 52-61.
95. Dave UP, Jenkins NA, Copeland NG. Gene therapy insertional mutagenesis insights. Science 2004; 303(5656): 333.
96. Mcswiggen, J., Beigelman, J., Thompson, J. RNA interference mediated inhibition of MDR P-glycoprotein gene expression using short interfering nucleic acid (siRNA). WO03070884 (2003).
97. Coffey, M., Thompson, B. Sensitization of chemotherapeutic agent resistant neoplastic cells with a virus. US20110243890 (2011).
98. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971; 285(21): 1182-6.
99. Liu Y, Deisseroth A. Tumor vascular targeting therapy with viral vectors. Blood 2006; 107(8): 3027-33.
100. Pradeep CR, Sunila ES, Kuttan G. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies. Integr Cancer Ther 2005; 4(4): 315-21.
101. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1(1): 27-31.
102. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407(6801): 249-57.
103. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29(6 Suppl 16): 15-8.
104. Cao Y. Angiogenesis: What can it offer for future medicine? Exp Cell Res 2010; 316(8): 1304-8.
105. Gridelli C, Maione P, Del Gaizo F, Colantuoni G, Guerriero C, Ferrara C, et al. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer. Oncologist 2007; 12(2): 191-200.
106. Kramer I, Lipp HP. Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer. J Clin Pharm Ther 2007; 32(1): 1-14.
107. Gardlik R, Celec P, Bernadic M. Targeting angiogenesis for cancer (gene) therapy. Bratisl Lek Listy 2011; 112(8): 428-34.
108. Kim WJ, Yockman JW, Jeong JH, Christensen LV, Lee M, Kim YH, et al. Anti-angiogenic inhibition of tumor growth by systemic delivery of PEI-g-PEG-RGD/pCMV-sFlt-1 complexes in tumorbearing mice. J Control Release 2006; 114(3): 381-8.
109. Feldman AL, Friedl J, Lans TE, Libutti SK, Lorang D, Miller MS, et al. Retroviral gene transfer of interferon-inducible protein 10 inhibits growth of human melanoma xenografts. Int J Cancer 2002; 99(1): 149-53.
110. Okada Y, Ueno H, Katagiri M, Oneyama T, Shimomura K, Sakurai S, et al. Experimental study of antiangiogenic gene therapy targeting VEGF in oral cancer. Odontology 2010; 98(1): 52-9.
111. Yang L, Wang L, Su XQ, Chen XC, Li D, Luo ST, et al. Suppression of ovarian cancer growth via systemic administration with liposome-encapsulated adenovirus-encoding endostatin. Cancer Gene Ther 2010; 17(1): 49-57.
112. Liu LL, Smith MJ, Sun BS, Wang GJ, Redmond HP, Wang JH. Combined IFN-gamma-endostatin gene therapy and radiotherapy attenuates primary breast tumor growth and lung metastases via enhanced CTL and NK cell activation and attenuated tumor angiogenesis in a murine model. Ann Surg Oncol 2009; 16(5): 1403-11.
113. Bai RZ, Wu Y, Liu Q, Xie K, Wei YQ, Wang YS, et al. Suppression of lung cancer in murine model: Treated by combination of recombinant human endostatin adenovirus with low-dose cisplatin. J Exp Clin Cancer Res 2009; 28: 31.
114. Sangro B, Mazzolini G, Ruiz J, Herraiz M, Quiroga J, Herrero I, et al. Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol 2004; 22(8): 1389-97.
115. Anwer K, Barnes MN, Fewell J, Lewis DH, Alvarez RD. Phase-I clinical trial of IL-12 plasmid/lipopolymer complexes for the treatment of recurrent ovarian cancer. Gene Ther 2010; 17(3): 360-9.
116. Harding, T., Jooss, K., Lalani, A., Donahue, B. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes. WO2005000220 (2005).
117. Harding, T. Vector-mediated delivery of polynucleotides encoding soluble VEGF receptors. US20060110364 (2006).
118. Lee, J.J., Lee, J., Lee, K., Hong, Y., Jin, X. Therapeutic agent for cancer, inflammation and auto-immune disease. US20080248024 (2008).
119. Harats, D., Greenberger, S., Breitbart, E., Bangio, L., Peled, M. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis. US20110207985 (2011).
120. Folkman, M., O'Reilly, M. Therapeutic antiangiogenic endostatin compositions. US7495089 (2009).
121. Xu, R., Sun, X., Fan, S., Kung, H., Krissansen, G., Wan Fung, P. Adeno-associated virus mediated B7.1 vaccination synergizes with angiostatin to eradicate disseminated liver metastatic cancers. US20040156828 (2004).
122. Jo, D., Lee, J.M., Park, K., Duong, M.T. Cell-permeable endostatin recombinant protein, a polynucleotide encoding the same, and anticancer preparation containing the same as an active component. US20110092441 (2011).
123. Prados J, Melguizo C, Boulaiz H, Marchal JA, Aranega A. Cancer gene therapy: Strategies and clinical trials. Cell Mol Biol (Noisy-legrand) 2005; 51(1): 23-36.
124. Portsmouth D, Hlavaty J, Renner M. Suicide genes for cancer therapy. Mol Aspects Med 2007; 28(1): 4-41.
125. Vassaux G, Lemoine NR. Gene therapy for carcinoma of the breast: Genetic toxins. Breast Cancer Res 2000; 2(1): 22-7.
126. Rosenberg E, Hawkins W, Holmes M, Amir C, Schmidt-Ullrich RK, Lin PS, et al. Radiosensitization of human glioma cells in vitro and in vivo with acyclovir and mutant HSV-TK75 expressed from adenovirus. Int J Radiat Oncol Biol Phys 2002; 52(3): 831-6.
127. Boucher PD, Shewach DS. In vitro and in vivo enhancement of ganciclovir-mediated bystander cytotoxicity with gemcitabine. Mol Ther 2005; 12(6): 1064-71.
128. Fulci G, Breymann L, Gianni D, Kurozomi K, Rhee SS, Yu J, et al. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci USA 2006; 103(34): 12873-8.
129. Robson T, Worthington J, McKeown SR, Hirst DG. Radiogenic therapy: Novel approaches for enhancing tumor radiosensitivity. Technol Cancer Res Treat 2005; 4(4): 343-61.
130. Park SY, Lee W, Lee J, Kim IS. Combination gene therapy using multidrug resistance (MDR1) gene shRNA and herpes simplex virus-thymidine kinase. Cancer Lett 2008; 261(2): 205-14.
131. Huber BE, Austin EA, Richards CA, Davis ST, Good SS. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: Significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci USA 1994; 91(17): 8302-6.
132. Djeha AH, Hulme A, Dexter MT, Mountain A, Young LS, Searle PF, et al. Expression of Escherichia coli B nitroreductase in established human tumor xenografts in mice results in potent antitumoral and bystander effects upon systemic administration of the prodrug CB1954. Cancer Gene Ther 2000; 7(5): 721-31.
133. Prosser GA, Copp JN, Syddall SP, Williams EM, Smaill JB, Wilson WR, et al. Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954. Biochem Pharmacol 2010; 79(5): 678-87.
134. DeBenedetti, A., DeFatta, R.J. Cancer gene therapy based on translational control of a suicide gene. US7592320 (2009).
135. Lowenstein, P., Castro, M. Combined gene therapy for the treatment of macroscopic gliomas. EP2338524 (2011).
136. Fabbro D, García-Echeverría C. Targeting protein kinases in cancer therapy. Curr Opin Drug Discov Devel 2002; 5(5): 701-12.
137. Shen, Y., Laquerre, S., Omer, C.A., Amy, M., Delaney, A. Candida kefyr cytosine deaminase. WO2004061079 (2004).
138. Erbs, P. Polypeptide having an improved cytosine deaminase activity. US20100330031 (2010).
139. Dachs GU, Hunt MA, Syddall S, Singleton DC, Patterson AV. Bystander or no bystander for gene directed enzyme prodrug therapy. Molecules 2009; 14(11): 4517-45.
140. Blaese, R., Culver, K.W. Bystander effect tumoricidal therapy by expressing an HSV-tk gene. WO93021959 (1993).
141. Kim HP, Frankel AE, Hogge DE. A diphtheria toxin interleukin-3 fusion protein synergizes with tyrosine kinase inhibitors in killing leukemic progenitors from BCR/ABL positive acute leukemia. Leuk Res 2010; 34(8): 1035-42.
142. Boulaiz H, Prados J, Marchal JA, Garcia AM, Alvarez L, Melguizo C, et al. Transfection of MS-36 melanoma cells with gef gene inhibits proliferation and induces modulation of the cell cycle. Cancer Sci 2003; 94(6): 564-8.
143. Prados J, Melguizo C, Rama A, Ortiz R, Boulaiz H, Rodriguez-Serrano F, et al. Combined therapy using suicide gef gene and paclitaxel enhances growth inhibition of multicellular tumor spheroids of A-549 human lung cancer cells. Int J Oncol 2008; 33(1): 121-7.
144. Boulaiz H, Prados J, Marchal JA, Melguizo C, Concha A, Carrillo E, et al. Modulation of Ki-67 expression and morphological changes induced by gef gene in MCF-7 human breast cancer cells. Cell Mol Biol (Noisy-le-grand) 2005; 51(1): 87-92.
145. Boulaiz H, Prados J, Melguizo C, Garcia AM, Marchal JA, Ramos JL, et al. Inhibition of growth and induction of apoptosis in human breast cancer by transfection of gef gene. Br J Cancer 2003; 89(1): 192-8.
146. Prados J, Melguizo C, Rama AR, Ortiz R, Segura A, Boulaiz H, et al. Gef gene therapy enhances the therapeutic efficacy of doxorubicin to combat growth of MCF-7 breast cancer cells. Cancer Chemother Pharmacol 2010; 66(1): 69-78.
147. Prados J, Melguizo C, Ortiz R, Boulaiz H, Carrillo E, Segura A, et al. Regression of established subcutaneous B16-F10 murine melanoma tumors after gef gene therapy associated with the mitochondrial apoptotic pathway. Exp Dermatol 2010; 19(4): 363-71.
148. Agu CA, Klein R, Lengler J, Schilcher F, Gregor W, Peterbauer T, et al. Bacteriophage-encoded toxins: The lambda-holin protein causes caspase-independent non-apoptotic cell death of eukaryotic cells. Cell Microbiol 2007; 9(7): 1753-65.
149. Ortiz R, Prados J, Melguizo C, Rama AR, Segura A, Rodriguez-Serrano F, et al. The cytotoxic activity of the phage E protein sup press the growth of murine B16 melanomas in vitro and in vivo. J Mol Med (Berl) 2009; 87(9): 899-911.
150. Rohn JL, Zhang YH, Leliveld SR, Danen-van Oorschot AA, Henriquez NV, Abrahams JP, et al. Relevance of apoptin's integrity for its functional behavior. J Virol 2005; 79(2): 1337-8.
151. Noteborn MH. Apoptin acts as a tumor-specific killer: Potentials for an anti-tumor therapy. Cell Mol Biol (Noisy-le-grand) 2005; 51(1): 49-60.
152. Aranega, A., Boulaiz, H., Melguizo C., Ortiz, R., Prados, J.C., Rama, A.R. E gene for anti-tumor therapy. ES2343929 (2010).
153. Rama AR, Prados J, Melguizo C, Burgos M, Alvarez PJ, Rodriguez-Serrano F, et al. Synergistic antitumoral effect of combination E gene therapy and Doxorubicin in MCF-7 breast cancer cells. Biomed Pharmacother 2011; 65(4): 260-70.
154. Rama AR, Prados J, Melguizo C, Ortiz R, Alvarez PJ, Rodriguez-Serrano F, et al. E phage gene transfection enhances sensitivity of lung and colon cancer cells to chemotherapeutic agents. Int J Oncol 2010; 37(6): 1503-14.
155. Hubertus, M., Noteborn, M., Adriana, A., Oorschot, D.V., Rohn, J.L., Weiss, B., Toschi, L. Apoptin-associating protein. US7741440 (2010).
156. Hubertus, M., Noteborn, M., Rohn, J.L., Mumberg, D., Donner, P. Modifications of apoptin. US20100279947 (2010).
157. Immonen A, Vapalahti M, Tyynela K, Hurskainen H, Sandmair A, Vanninen R, et al. AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: A randomised, controlled study. Mol Ther 2004; 10(5): 967-72.
158. Rainov NG. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 2000; 11(17): 2389-401.
159. Klatzmann D, Valery CA, Bensimon G, Marro B, Boyer O, Mokhtari K, et al. A phase I/II study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma. Hum Gene Ther 1998; 9(17): 2595-604.
160. Ayala G, Satoh T, Li R, Shalev M, Gdor Y, Aguilar-Cordova E, et al. Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer. Mol Ther 2006; 13(4):716-28.
161. Nasu Y, Saika T, Ebara S, Kusaka N, Kaku H, Abarzua F, et al. Suicide gene therapy with adenoviral delivery of HSV-tK gene for patients with local recurrence of prostate cancer after hormonal therapy. Mol Ther 2007; 15(4): 834-40.
162. Pandha HS, Martin LA, Rigg A, Hurst HC, Stamp GW, Sikora K, et al. Genetic prodrug activation therapy for breast cancer: A phase I clinical trial of erbB-2-directed suicide gene expression. J Clin Oncol 1999; 17(7): 2180-9.
163. Crystal RG, Hirschowitz E, Lieberman M, Daly J, Kazam E, Henschke C, et al. Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine. Hum Gene Ther 1997; 8(8): 985-1001.
164. Haberkorn U, Oberdorfer F, Gebert J, Morr I, Haack K, Weber K, et al. Monitoring gene therapy with cytosine deaminase: In vitro studies using tritiated-5-fluorocytosine. J Nucl Med 1996; 37(1): 87-94.
165. Nemunaitis J, Cunningham C, Senzer N, Kuhn J, Cramm J, Litz C, et al. Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients. Cancer Gene Ther 2003; 10(10): 737-44.